Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05144334 · ClinicalTrials.gov registry record · Phase 1
A Study of BTX-1188 in Subjects With Advanced Malignancies
A Phase 1 study, sponsored by Biotheryx.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT05144334: Clinical Trial Phase 1 study, sponsored by Biotheryx.
NCT05144334 is a Phase 1 study that was terminated before completion, run by Biotheryx. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05144334, a Phase 1 study, was terminated before completion, sponsored by Biotheryx.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a multicenter, open label, nonrandomized, sequential dose escalation, multiple dose study designed to evaluate the safety, toxicity, and pharmacokinetics (PK) as well as preliminary efficacy of BTX-1188 orally administered in subjects with advanced malignancies.
Interventions
- DRUG BTX-1188
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2022-01-24 |
| Est. Completion | 2023-09-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05144334
The ClinicalTrials.gov registry entry for NCT05144334 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biotheryx, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BTX-1188 is the first listed.
NCT05144334 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05144334 about?
NCT05144334 is a clinical study titled "A Study of BTX-1188 in Subjects With Advanced Malignancies". This is a multicenter, open label, nonrandomized, sequential dose escalation, multiple dose study designed to evaluate the safety, toxicity, and pharmacokinetics (PK) as well as preliminary efficacy of BTX-1188 orally administered in subjects with advanced malignancies.
What is the current status of trial NCT05144334?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2022-01-24. Estimated completion is 2023-09-12.
What interventions are being tested in trial NCT05144334?
The interventions under investigation include: BTX-1188 (DRUG).
Who is sponsoring clinical trial NCT05144334?
This trial is sponsored by Biotheryx, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.